NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/12/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,674.86 mln
Float219 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-2.23
Borderline
1-Year Forecast
16.33
Transformational upside
Relative Strength
87
/ 100
Strongly outperforming
Debt / Equity
1.40
Elevated leverage
ROE
-38.45
Deeply negative
Business Description
Ardelyx is a pharmaceutical company based in Waltham, Massachusetts, that creates and sells treatments for conditions that have few or no existing solutions, both in the United States and abroad. Its two main products are IBSRELA, used to treat irritable bowel syndrome with constipation, and XPHOZAH, which helps control phosphorus levels in adults with chronic kidney disease who are on dialysis. Founded in 2007 under the name Nteryx, the company rebranded as Ardelyx in 2008.
